Filing summary
Entity and period: The supplied filing is Synthetic Biologics, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed March 30, 2012. It is not a Theriva Biologics, Inc. filing; the company name in the request metadata does not match the filing.
Business context
Synthetic Biologics was a pre-revenue biotechnology company developing treatments for serious diseases. Its programs included a preclinical synthetic DNA-based PAH candidate under a new collaboration with Intrexon; Phase II Trimesta studies for relapsing-remitting MS and cognitive dysfunction; Meda-partnered flupirtine development for fibromyalgia; and AEN-100 zinc acetate development for ALS. In February 2012, the company changed its name from Adeona Pharmaceuticals to Synthetic Biologics. It sold its clinical laboratory business in March 2012.
Financial highlights
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Continuing-operations revenue | $0 | $2.614 million |
| General and administrative expense | $2.588 million | $2.117 million |
| Research and development expense | $3.340 million | $1.580 million |
| Loss from continuing operations | $7.626 million | $1.195 million |
| Loss from discontinued operations | $523,000 | $516,000 |
| Net loss | $8.149 million | $1.711 million |
| Net loss per share | $0.29 | $0.08 |
| Cash used in operating activities | $2.875 million | $1.145 million |
| Cash at year-end | $6.678 million | $2.649 million |
FY 2010 continuing revenue included $2.125 million net flupirtine license revenue and $489,000 in grant revenue. FY 2011 R&D expense included a $1.684 million noncash charge for shares issued to Intrexon. G&A included $919,000 of stock-based compensation, including a one-time $398,000 option-modification charge. Other expense was $1.698 million, largely reflecting warrant-related charges.
Separately, the clinical laboratory business reported revenue of $1.169 million in 2011 and $551,000 in 2010, with losses of $523,000 and $516,000, respectively; these results were classified as discontinued operations.
Balance sheet and liquidity
At December 31, 2011, total assets were $7.476 million, total liabilities were $417,000, and stockholders’ equity was $7.059 million. Current assets were $7.122 million versus current liabilities of $417,000. The balance sheet reported no debt. Contractual obligations disclosed for 2012–2016 totaled $79,000, primarily license commitments.
The company raised $7.5 million gross through equity offerings in 2011. Management stated that year-end cash was expected to fund planned operations for at least 12 months, but noted that the estimate depended on uncertain development costs and financing availability. By March 26, 2012, cash was approximately $6.9 million after warrant exercises raised $1.4 million gross.
Changes, outlook and risks
- Net loss increased substantially year over year as continuing revenue fell to zero and R&D and G&A expenses rose. The company attributed much of the R&D increase to the noncash Intrexon share issuance; warrant accounting also contributed to other expense.
- The Intrexon agreement granted a worldwide license for the PAH program. Synthetic Biologics issued Intrexon shares equal to 9.995% of post-issuance shares and agreed to share 50% of cumulative net product profits and certain sublicense revenue. Additional shares may be issued upon dosing the first patient in a qualifying Phase II study.
- The company said the relapsing-remitting MS Phase II trial had completed enrollment at 164 patients and was funded by grants exceeding $8 million. The cognitive dysfunction Phase II trial began enrollment in January 2012; the company pledged approximately $500,000 over three years. The ALS program was preparing for clinical studies and carried a company commitment of approximately $400,000 for the first Phase II/III stage.
- Management provided no revenue or earnings guidance. It expected continued operating losses and identified potential need for additional capital. No assurance was given that financing would be available on acceptable terms.
- Key risks include early-stage and unproven DNA-based therapy, clinical and regulatory failure or delays, dependence on collaborators and grant funding, manufacturing and intellectual-property uncertainty, limited revenue sources, likely dilution from future financing, and thinly traded stock. The company also disclosed multiple recent executive changes.
- The company reported effective disclosure controls and internal control over financial reporting as of year-end. The independent auditor issued an unqualified opinion on the financial statements; the auditor did not attest to internal control effectiveness.
Investor verification priorities
- Confirm the intended issuer: this filing is for Synthetic Biologics, not Theriva Biologics.
- Review the audited statements and discontinued-operations note to distinguish continuing business results from laboratory revenue and losses.
- Assess the cash runway assumptions against current clinical plans, the laboratory sale’s $700,000 two-year non-recourse note, and subsequent financing or warrant activity.
- Verify Intrexon’s equity, profit-sharing, milestone-share, and termination provisions, and the resulting potential dilution.
- Check clinical-trial status, funding sufficiency, and regulatory or intellectual-property developments for each program; the filing’s market-size estimates are company-reported estimates, not realized revenue.